TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Debt Components
- 2024-12-31: Long-term Debt, Current MaturitiesUSD $2.82M; Long-term Debt, Excluding Current MaturitiesUSD $4.67M; Long-term DebtUSD $8.65M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2024-09-30: Long-term Debt, Current MaturitiesUSD $2.82M; Long-term Debt, Excluding Current MaturitiesUSD $5.17M; Long-term DebtUSD $9.36M; Long-Term Debt, Maturity, Year OneUSD $2.82M.
- 2024-06-30: Long-term Debt, Current MaturitiesUSD $2.82M; Long-term Debt, Excluding Current MaturitiesUSD $5.67M; Long-term DebtUSD $10.06M; Long-Term Debt, Maturity, Year OneUSD $2.82M.
- 2024-03-31: Long-term Debt, Current MaturitiesUSD $2.82M; Long-term Debt, Excluding Current MaturitiesUSD $6.16M; Long-term DebtUSD $10.77M; Long-Term Debt, Maturity, Year OneUSD $2.82M.
TONIX PHARMACEUTICALS HOLDING CORP. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Long-Term Debt, Maturity, Year Three USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate During Period pure | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Convertible, Conversion Price USD/shares | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD | Notes Payable, Related Parties, Current USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $2.82M | $4.67M | $8.65M | (m) | (m) | (m) | $5.83M | $1.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $2.82M | $5.17M | $9.36M | $2.82M | $5.83M | $705.00K | $6.54M | $1.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $2.82M | $5.67M | $10.06M | $2.82M | $5.83M | $1.41M | $7.24M | $1.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $2.82M | $6.16M | $10.77M | $2.82M | $5.83M | $2.12M | $7.95M | $1.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $2.35M | $6.56M | $11.00M | (m) | (m) | (m) | $8.65M | $2.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $2.35M | $2.82M | (m) | (m) | (m) | $5.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $280.00K |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $132.42K | $280.00K |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $280.00K |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $280.00K |
| 2013-08-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.00K | (m) | (m) | (m) | (m) | (m) |
| 2013-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $710.00K | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.30 | (m) | $0.00 |
| 2012-11-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.00% | (m) | (m) | (m) | (m) |
| 2012-11-14 | (m) | (m) | (m) | (m) | (m) | (m) | $320.00K | (m) | (m) | $390.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.62 | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.62 | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.62 | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |